|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009566,
umls-concept:C0012634,
umls-concept:C0034656,
umls-concept:C0036043,
umls-concept:C0439849,
umls-concept:C0445223,
umls-concept:C0663182,
umls-concept:C1292734,
umls-concept:C1299003,
umls-concept:C1522326,
umls-concept:C1552599,
umls-concept:C1704787,
umls-concept:C2603343
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2007-6-11
|
|
pubmed:abstractText |
To investigate the safety and efficacy of daclizumab (Zenapax, humanized anti-Tac, HAT) in controlling the ocular manifestations of Behçet's disease.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0927-3948
|
|
pubmed:author |
pubmed-author:AltemareChandraC,
pubmed-author:BamjiAlison TAT,
pubmed-author:BuggageRonald RRR,
pubmed-author:ChanChi-ChaoCC,
pubmed-author:Levy-ClarkeGraceG,
pubmed-author:NussenblattRobert BRB,
pubmed-author:RaghebJackJ,
pubmed-author:SenHatice NHN,
pubmed-author:SranPusphaP,
pubmed-author:SrivastavaSunil KSK,
pubmed-author:SuhlerEric BEB,
pubmed-author:ThompsonDarby J SDJ,
pubmed-author:UrseaRoxanaR,
pubmed-author:VelezGiselaG,
pubmed-author:WaldmannThomasT
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
63-70
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17558830-Adolescent,
pubmed-meshheading:17558830-Adult,
pubmed-meshheading:17558830-Aged,
pubmed-meshheading:17558830-Antibodies, Monoclonal,
pubmed-meshheading:17558830-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17558830-Behcet Syndrome,
pubmed-meshheading:17558830-Child,
pubmed-meshheading:17558830-Dose-Response Relationship, Drug,
pubmed-meshheading:17558830-Double-Blind Method,
pubmed-meshheading:17558830-Female,
pubmed-meshheading:17558830-Fluorescein Angiography,
pubmed-meshheading:17558830-Follow-Up Studies,
pubmed-meshheading:17558830-Fundus Oculi,
pubmed-meshheading:17558830-Humans,
pubmed-meshheading:17558830-Immunoglobulin G,
pubmed-meshheading:17558830-Immunosuppressive Agents,
pubmed-meshheading:17558830-Infusions, Intravenous,
pubmed-meshheading:17558830-Male,
pubmed-meshheading:17558830-Middle Aged,
pubmed-meshheading:17558830-Time Factors,
pubmed-meshheading:17558830-Treatment Outcome,
pubmed-meshheading:17558830-Uveitis
|
|
pubmed:articleTitle |
A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
|
|
pubmed:affiliation |
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892-1857, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, N.I.H., Intramural
|
